STAT5A and cancer: Since most STAT5 inhibitors are not yet extensively validated for their safety and efficacy in the treatment of cancer patients, and their studies have mostly been focused on targeting haematological malignancies, more research is required to develop novel therapies for STAT5-dependent cancers.